Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication

Journal of Thrombosis and Thrombolysis

Volumn 41, Issue 2, 2016, Pages 241-247

  Cuker, Adam ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apixaban; Dabigatran; Edoxaban; Measurement; Monitoring; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; ECARIN; EDOXABAN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT AGENT; RIVAROXABAN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 10A INHIBITOR; VITAMIN K GROUP;

ANTI XA ACTIVITY; ARTICLE; BIOASSAY; BLOOD CLOTTING PARAMETERS; DIAGNOSTIC KIT; DILUTE THROMBIN TIME; DRUG BLOOD LEVEL; DRUG MONITORING; EVIDENCE BASED PRACTICE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEASUREMENT ACCURACY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; FACTOR XA INHIBITORS; HUMANS; PARTIAL THROMBOPLASTIN TIME; THROMBIN TIME; VITAMIN K;

EID: 84956963407     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1282-7     Document Type: Article

References (35)

1. Chai-Adisaksopha C, Crowther M, Isayama I, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124:2450–2458
2. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100:1419–1426
3. Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53:1–16
4. Kowalsk K, Nielsen J, Roy A, et al (2014) Apixaban exposure and anti-Xa activity in nonvalvular atrial fibrillation patients: an application of population PK/PD analysis [abstract]. J Pharmacokinet Pharmacodyn 41:S19. Abstract M-027
5. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S (2010) Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104:633–641
6. Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, Douketis J, Schulman S, Eikelboom JW (2015) Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 13:353–359
7. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, Investigators RE-LY (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol 63:321–328
8. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM (2015) Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385:2288–2295
9. Cuker A, Siegal DM (2015) Monitoring and reversal of direct oral anticoagulants. Hematol Am Soc Hematol Educ Progr
10. Cuker A, Siegal DM, Crowther MA, Garcia DA (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K antagonist oral anticoagulants. J Am Coll Cardiol 64:1128–1139
11. Cuker A, Husseinzadeh H (2015) Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 39:288–294
12. Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K (2015) The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 47:355–364
13. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S (2013) Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 11:1493–1502
14. Favaloro EJ, Bonar R, Butler J, Marsden K (2013) Laboratory testing for new oral anticoagulants: a review of current practice. Pathology 45:435–437
15. Douxfils J, Mullier F, Robert S, Chatelain C, Dogné JM (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107:985–997
16. Harenberg J, Giese C, Marx S, Krämer R (2012) Determination of dabigatran in human plasma samples. Semin Thromb Hemost 38:16–22
17. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg EM, Onelöv L, Rönquist-Nii Y, Pohanka A, Beck O, Hjemdahl P, Malmström RE (2013) Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 69:1875–1881
18. Jones SD, Eaddy NS, Chan GT (2012) Dabigatran: laboratory monitoring. Pathology 44:578–580
19. Hapgood G, Butler J, Malan E, Chunilal S, Tran H (2013) The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 110:308–315
20. Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L (2013) Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 59:807–814
21. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standarisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. doi:10.1111/jth.12149
22. Molenaar PJ, Dinkelaar J, Leyte A (2012) Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 50:1799–1807
23. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné JM, Mullier F (2013) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 110:723–731
24. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743–753
25. Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S (2011) Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost 105:1080–1090
26. Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM (2015) Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother 49:777–783
27. College of American Pathologists (2013) Surveys Participant Summary for CGE, CGL, GCS, and ACM. College of American Pathologists, Northfield
28. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ (2007) Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex vivo flow chamber. Thromb Haemost 98:883–888
29. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E (2010) Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 103:815–825
30. Tripodi A, Chantarangkul V, Guinet C, Samama MM (2011) The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 9:226–228
31. Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C, Gourmelin Y, Martinoli JL, Laboratories Rivaroxaban Prothrombin Time Field Trial (2012) Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 18:150–158
32. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S (2012) In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 129:e77–e82
33. Tripodi A, Padovan L, Veena C, Scalambrino E, Testa S, Peyvandi F (2015) How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res 135:1186–1190
34. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S (2014) Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamics study based on peak and trough plasma levels. Thromb Haemost 111:1133–1140
35. Barrett YC, Wang Z, Knabb RM (2013) A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 19:522–528